Half-life and safety of canakinumab in pediatric patients: Comment on the article by Ilowite et al

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 857-858

  Brunner, Hermine ^a   Graham Lomax, Kathleen ^b   Levy, Stephane ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; RILONACEPT; ANTIRHEUMATIC AGENT; HYBRID PROTEIN;

CINCA SYNDROME; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; PRIORITY JOURNAL; ARTHRITIS, JUVENILE; FEMALE; MALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; FEMALE; HUMANS; MALE; RECOMBINANT FUSION PROTEINS;

EID: 84923612737     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38992     Document Type: Letter

References (6)

1. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66: 2570-9.
2. Ilaris (canakinumab) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals; 2014.
3. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
4. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
5. Novartis Pharmaceuticals and Pediatric Rheumatology International Trials Organization. Flare prevention study of canakinumab in patients with active systemic juvenile idiopathic arthritis (SJIA) (β-SPECIFIC 2). URL: http://www.clinicaltrials.gov/ct2/show/study/NCT00889863.
6. Wulffraat NM, Ruperto N, Brunner HI, Oliveira S, Uziel Y, Nistala K, et al. Maintenance of efficacy by canakinumab treatment in systemic juvenile idiopathic arthritis patients [abstract]. Ann Rheum Dis 2014; 73 Suppl 2: 130.